Michael Burkes Brophy Sells 920 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 920 shares of the company’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $186.68, for a total value of $171,745.60. Following the transaction, the chief financial officer directly owned 69,189 shares in the company, valued at $12,916,202.52. This trade represents a 1.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total value of $148,561.35.
• On Thursday, October 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The shares were sold at an average price of $187.16, for a total value of $92,644.20.
• On Tuesday, October 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $113,145.90.
• On Tuesday, September 30th, Michael Burkes Brophy sold 2,491 shares of Natera stock. The stock was sold at an average price of $162.05, for a total transaction of $403,666.55.
• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00.
• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The stock was sold at an average price of $139.81, for a total transaction of $282,276.39.

Natera Price Performance

Shares of Natera stock opened at $192.51 on Friday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $198.99. The business has a 50-day moving average of $171.29 and a two-hundred day moving average of $160.37. The company has a market capitalization of $26.42 billion, a P/E ratio of -100.79 and a beta of 1.74.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the company earned ($0.30) earnings per share. The firm’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Saturday. Stephens reiterated an “overweight” rating and set a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Cowen reiterated a “buy” rating on shares of Natera in a report on Friday, August 8th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Finally, Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $197.59.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NTRA. GAMMA Investing LLC grew its stake in Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock valued at $120,000 after purchasing an additional 207 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in Natera in the first quarter valued at approximately $6,753,000. Golden State Wealth Management LLC grew its stake in Natera by 103.4% in the first quarter. Golden State Wealth Management LLC now owns 1,017 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 517 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in Natera in the first quarter valued at approximately $1,640,000. Finally, Artemis Investment Management LLP grew its stake in Natera by 54.1% in the first quarter. Artemis Investment Management LLP now owns 198,778 shares of the medical research company’s stock valued at $28,109,000 after purchasing an additional 69,751 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.